AN EMERGING MARINE BIOTECHNOLOGY: MARINE DRUG DISCOVERY
Marine natural resources offer an opportunity to discover a novel chemical diversity with interesting pharmacologically active compounds to treat many diseases such as cancer, inflammation, bacterial and parasitic infections, and many other diseases. Marine drug discovery is a rising area in marine biotechnology. Several hits of marine-derived drug compounds were approved; two of them are Ziconotide and Trabectedin. In 2004, Ziconotide was approved as pain treatment drugs in the United States and Europe. Then, in 2007, Trabectedin was also approved as anticancer drug in Europe. The main problem in marine drug discovery research is material supply problem. Up till now, strategies to overcome the problem are “Pharmaceutical aquaculture” of biologically active marine biota and chemical synthesis approach. Chemical synthesis approach is feasible solution to be used, especially when working with less complex structure of compounds. However, when working with structurally complex compounds where total or even semi synthesis was very difficult to be provided, aquaculture can be a solution. Currently, the use of microbiology, biochemistry, genetic, bioinformatics, genomic and meta-genomic has been intensifying in order to have a better result in marine natural product drug discovery. As chemical synthesis needs an expensive investment of advanced technology and highly skilled human resources, thus pharmaceutical aquaculture is more practicable to overcome the material supply insufficiency in Indonesia. Up till now, many Indonesian marine bioprospectors have been working with culturable marine microorganism to produce bioactive compounds and some others starting to work with genomic and metagenomic-based drug discovery.
|B1707269||Koleksi Digital||Archivelago Indonesia Marine Library - Perpustakaan Kementerian Kelautan dan Perikanan||Available|
No other version available